|Huge Expansion plan, Exp Revenue CAGR 60+%||High Plegded Share (57%)|
|Colaboration with Ajinomoto Unichem||High Borrowing (D/E ratio - 0.35)|
|Strong presence in Paracetamol, Ibuprofcen, Metf||Direct competition with Asian Cos, Quality Control a Must|
|Good growth in API, FD, and PFI segment||High Dependence on 2 drugs (Paracetamol, Ibuprofen)|
|Strong growth of generics Market||High contribution of Export - Currency fluctuations|
HDFC Sec has came up with a research report on it.
To me seems a good short-medium term pick.
Views invited on it.